These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36831492)

  • 1. Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience.
    Mingrone G; Astarita A; Colomba A; Catarinella C; Cesareo M; Airale L; Paladino A; Leone D; Vallelonga F; Bringhen S; Gay F; Veglio F; Milan A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction.
    Astarita A; Mingrone G; Airale L; Vallelonga F; Covella M; Catarinella C; Cesareo M; Bruno G; Leone D; Giordana C; Cetani G; Salvini M; Gay F; Bringhen S; Rabbia F; Veglio F; Milan A
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
    Muramatsu A; Kobayashi T; Kawaji-Kanayama Y; Uchiyama H; Sasaki N; Uoshima N; Nakao M; Takahashi R; Shimura K; Kaneko H; Kiyota M; Wada K; Chinen Y; Hirakawa K; Fuchida SI; Shimazaki C; Mizutani S; Tsukamoto T; Shimura Y; Taniwaki M; Teramukai S; Kuroda J;
    Leuk Lymphoma; 2022 Jul; 63(7):1678-1685. PubMed ID: 35147475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.
    Bruno G; Bringhen S; Maffei I; Iannaccone A; Crea T; Ravera A; Astarita A; Vallelonga F; Salvini M; Gay F; Veglio F; Milan A
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients.
    Mingrone G; Astarita A; Airale L; Maffei I; Cesareo M; Crea T; Bruno G; Leone D; Avenatti E; Catarinella C; Salvini M; Cetani G; Gay F; Bringhen S; Veglio F; Vallelonga F; Milan A
    Front Cardiovasc Med; 2021; 8():645678. PubMed ID: 33969010
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
    Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
    J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.
    Tantawy M; Chekka LM; Huang Y; Garrett TJ; Singh S; Shah CP; Cornell RF; Baz RC; Fradley MG; Waheed N; DeRemer DL; Yuan L; Langaee T; March K; Pepine CJ; Moreb JS; Gong Y
    Front Cardiovasc Med; 2021; 8():645122. PubMed ID: 33996940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.
    Kastritis E; Laina A; Georgiopoulos G; Gavriatopoulou M; Papanagnou ED; Eleutherakis-Papaiakovou E; Fotiou D; Kanellias N; Dialoupi I; Makris N; Manios E; Migkou M; Roussou M; Kotsopoulou M; Stellos K; Terpos E; Trougakos IP; Stamatelopoulos K; Dimopoulos MA
    Leukemia; 2021 May; 35(5):1418-1427. PubMed ID: 33589757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
    Cornell RF; Ky B; Weiss BM; Dahm CN; Gupta DK; Du L; Carver JR; Cohen AD; Engelhardt BG; Garfall AL; Goodman SA; Harrell SL; Kassim AA; Jadhav T; Jagasia M; Moslehi J; O'Quinn R; Savona MR; Slosky D; Smith A; Stadtmauer EA; Vogl DT; Waxman A; Lenihan D
    J Clin Oncol; 2019 Aug; 37(22):1946-1955. PubMed ID: 31188726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model.
    Yuan S; Zhou JY; Yang BZ; Xie ZL; Zhu TJ; Hu HX; Li R
    Front Oncol; 2023; 13():1043869. PubMed ID: 37025590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.
    Ling Y; Li R; Zhong J; Zhao Y; Chen Z
    Drug Chem Toxicol; 2022 Jul; 45(4):1443-1448. PubMed ID: 33108916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma.
    Takakuwa T; Otomaru I; Araki T; Miura A; Fujitani Y; Mochizuki Y; Miyagi Y; Senzaki H; Yamamura R
    Case Rep Hematol; 2019; 2019():1816287. PubMed ID: 31183224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.
    Imtiaz H; Khan M; Ehsan H; Wahab A; Rafae A; Khan AY; Jamil A; Sana MK; Jamal A; Ali TJ; Ansar I; Khan MM; Khouri J; Anwer F
    Onco Targets Ther; 2021; 14():4941-4960. PubMed ID: 34629878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study.
    Astarita A; Mingrone G; Airale L; Cesareo M; Colomba A; Catarinella C; Leone D; Gay F; Bringhen S; Veglio F; Milan A; Vallelonga F
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study.
    Terpos E; Stamatelopoulos K; Makris N; Georgiopoulos G; Ntanasis-Stathopoulos I; Gavriatopoulou M; Laina A; Eleutherakis-Papaiakovou E; Fotiou D; Kanellias N; Malandrakis P; Delialis D; Andreadou I; Kastritis E; Dimopoulos MA
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
    Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
    Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience.
    Batra A; Patel B; Addison D; Baldassarre LA; Desai N; Weintraub N; Deswal A; Hussain Z; Brown SA; Ganatra S; Agarwala V; Parikh PM; Fradley M; Ghosh A; Guha A
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34952868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
    Latif A; Kapoor V; Lateef N; Ahsan MJ; Usman RM; Malik SU; Ahmad N; Rosko N; Rudoni J; William P; Khouri J; Anwer F
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):30-45. PubMed ID: 33845729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.
    Mato A; Tang B; Azmi S; Yang K; Han Y; Zhang X; Roeker L; Wallis N; Stern JC; Hedrick E; Huang J; Sharman JP
    EJHaem; 2023 Feb; 4(1):135-144. PubMed ID: 36819172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.